drugset / Trial / NCT02944214

Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients

NCT02944214

Unknown 800 enrolled Shanghai 10th People's Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether febuxostat and benzbromarone could protect renal function in chinese, and which one could be better.

Timeline

Start
2016-10
Primary completion
2019-12
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Benzbromarone Small molecule 12.5 mg Oral
Subject Benzbromarone Small molecule 100 mg Oral
Subject Febuxostat Small molecule 10 mg Oral
Subject Febuxostat Small molecule 80 mg Oral